Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

Pfizer

Status and phase: Completed; Phase 1

Conditions: Obesity

Treatments: Other: Placebo; Drug: Liraglutide

Study type: Interventional

Funder types: Industry

Identifiers

NCT03041792

A9001498

Details and patient eligibility

About

This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.

Enrollment: 61 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and female subjects;
• Body Mass Index 30-40 kg/m2;

Exclusion criteria

• Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

61 participants in 2 patient groups, including a placebo group

Active

Experimental group

Description:

Liraglutide

Treatment:

Drug: Liraglutide

Placebo

Placebo Comparator group

Description:

Placebo comparator

Treatment:

Other: Placebo